PROM1 and hepatocellular carcinoma: In addition, after doxorubicin (DOX) treatment, the proportion of EpCAM+/CD133+ was significantly increased in the EpCAM−/CD133− nonstem HCC population, accompanied by more stemness properties and elevated tumor-forming ability [84].